Citations

Clear

6273 citation(s) found for "To, Andrew".

Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments
Tesfaye, Solomon , Dyck, Peter James , Kempler, Péter , Lauria, Giuseppe , Malik, Rayaz A. , Spallone, Vincenza , Vinik, Aaron I. , Bernardi, Luciano, Valensi, Paul, Group, on behalf of the Toronto Diabetic Neuropathy Expert, Feldman, Eva L. , Pop‐Busui, Rodica , Boulton, Andrew J.M. , Freeman, Roy L. , Horowitz, Michael , Group, on behalf of the Toronto Diabetic Neuropathy Expert, Pop-Busui, Rodica , Feldman, Eva L

Mayo Clinic

Diabetes Care | September 28, 2010 | Volume: 33 | Issue: 10 | Pages: 2285-2293

10.2337/dc10-1303 | PMID 20876709 Get It

Preceding the joint meeting of the 19th annual Diabetic Neuropathy Study Group of the European Association for the Study of Diabetes (NEURODIAB) and the 8th International Symposium on Diabetic Neuropathy in Toronto, Canada, 13–18 October 2009, expert panels were convened to provide updates on classification, definitions, diagnostic criteria, and treatments of diabetic peripheral neuropathies (DPNs), autonomic neuropathy, painful DPNs, and structural alterations in DPNs.
Fibrin D-Dimer Concentration, Deep Vein Thrombosis Symptom Duration, and Venous Thrombus Volume
Kurklinsky, Andrew K., Kalsi, Henna, Wysokiński, Waldemar E. , Mauck, Karen F. , Bhagra, Anjali , Havyer, Rachel D. , Thompson, Carrie A. , Hayes, Sharonne N. , McBane, Robert D. , Wysokinski, Waldemar , McBane, Robert , Hayes, Sharonne N

Mayo Clinic

Angiology | September 11, 2010 | Volume: 62 | Issue: 3 | Pages: 253-256

10.1177/0003319710382416 | PMID 20834027 Get It

Introduction: To determine the relationship between fibrin D-dimer levels, symptom duration, and thrombus volume, consecutive patients with incident deep venous thrombosis (DVT) were evaluated. Methods: In a cross-sectional study design, patient symptom onset was determined by careful patient questioning. Venous thrombosis was confirmed by compression duplex ultrasonography. Thrombus volume was estimated based on patient’s femur length using a forensic anthropology method. Fibrin D-dimer was measured by latex immunoassay. Results: 72 consecutive patients with confirmed leg DVT agreed to participate. The median symptom duration at the time of diagnosis was 10 days. The median D-dimer concentration was 1050 ng/dL. The median thrombus volume was 12.92 cm 3 . D-Dimer levels correlated with estimated thrombus volume (P < .0006 CI 0.12-0.41; R 2 adjusted = .15) but not symptom duration, patient’s age, or gender. Conclusions: Despite varying symptom duration prior to diagnosis, fibrin D-dimer remains a sensitive measure of venous thrombosis and correlates with thrombus volume.
Update on the diagnosis and treatment of Pneumocystis pneumonia
Carmona, Eva M. , Limper, Andrew H. , Carmona, Eva M

Mayo Clinic

Therapeutic Advances in Respiratory Disease | August 24, 2010 | Volume: 5 | Issue: 1 | Pages: 41-59

10.1177/1753465810380102 | PMID 20736243 Get It

Pneumocystis is an opportunistic fungal pathogen that causes an often-lethal pneumonia in immunocompromised hosts. Although the organism was discovered in the early 1900s, the first cases of Pneumocystis pneumonia in humans were initially recognized in Central Europe after the Second World War in premature and malnourished infants. This unusual lung infection was known as plasma cellular interstitial pneumonitis of the newborn, and was characterized by severe respiratory distress and cyanosis with little or no fever and no pathognomic physical signs. At that time, only anecdotal cases were reported in adults and usually these patients had a baseline malignancy that led to a malnourished state. In the 1960–1970s additional cases were described in adults and children with hematological malignancies, but Pneumocystis pneumonia was still considered a rare disease. However, in the 1980s, with the onset of the HIV epidemic, Pneumocystis prevalence increased dramatically and became widely recognized as an opportunistic infection that caused potentially life-treating pneumonia in patients with impaired immunity. During this time period, prophylaxis against this organism was more generally instituted in high-risk patients. In the 1990s, with widespread use of prophylaxis and the initiation of highly active antiretroviral therapy (HAART) in the treatment of HIV-infected patients, the number of cases in this specific population decreased. However, Pneumocystis pneumonia still remains an important cause of severe pneumonia in patients with HIV infection and is still considered a principal AIDS-defining illness. Despite the decreased number of cases among HIV-infected patients over the past decade, Pneumocystis pneumonia continues to be a serious problem in immunodeficient patients with other immunosuppressive conditions. This is mostly due to increased use of immunosuppressive medications to treat patients with autoimmune diseases, following bone marrow and solid organ transplantation, and in patients with hematological and solid malignancies. Patients with hematologic disorders and solid organ and hematopoietic stem cell transplantation are currently the most vulnerable groups at risk for developing this infection. However, any patient with an impaired immunity, such as those receiving moderate doses of oral steroids for greater than 4 weeks or those receiving other immunosuppressive medications are at also at significant risk.
Cancer registries: a novel alternative to long-term clinical trial follow-up based on results of a comparative study
Shi, Qian , Nelson, Heidi , Winchester, David P., Stewart, Andrew K., Young‐Fadok, Tonia M., Decker, Paul A. , You, Y. Nancy , Allen, Mark S. , Decker, Paul A. , Green, Erin M. , Holton, Sara , Ballman, Karla V. , Shi, Qian

Mayo Clinic

Clinical Trials | August 20, 2010 | Volume: 7 | Issue: 6 | Pages: 686-695

10.1177/1740774510380953 | PMID 20729254 Get It

Background Data collection and review were identified as major contributors to the cost of randomized clinical trials (RCTs). Purpose We proposed and assessed a novel alternative for long-term clinical trial follow-up based on the data captured through an accredited Cancer Registry (CR) that is part of the National Cancer Database (NCDB). Methods Patients from Mayo Clinic, Rochester, enrolled in the North Central Cancer Treatment Group N934653 (COST) trial (98 patients) and the American College of Surgeons Oncology Group Z0030 trial (55 patients) were included in the study. Demographic, treatment, and long-term outcome data were compared between the hospital-based CR and the RCTs’ databases. Concordances were used to estimate the agreement between two databases. Kaplan—Meier curves were plotted to examine the consistency of time-to-event long-term outcomes of the CR and RCT databases. Results High concordances (>95%) were observed for most demographic and treatment variables between the CR data and RCT data. The vital status concordances were 100% and 94.5% between the CR and COST and Z0030 databases, respectively. Three discrepant death dates were observed, one in the COST trial and two in the Z0030 trial. The concordances of disease-free status between the CR and RCT databases were 99.0% and 87.3%, and 15 discrepant disease recurrence cases were identified: 4 for COST and 11 for Z0030. Limitations The analysis has been focused on patients from a single site, Mayo Clinic, Rochester, enrolled in two large RCT evaluating surgical treatments. The findings herein need to be confirmed in a broader setting, such as multi-center, multi-registry including nonsurgical trials. Conclusions CR data were nearly identical to data from two randomized phase III trials in different disease types and conducted by two different cooperative groups. The NCDB Cancer Registries represent a feasible alternative for obtaining long-term follow-up data for large clinical trials. Clinical Trials 2010; 7: 686—695. http:// ctj.sagepub.com
EHRA Expert Consensus Statement on the management of cardiovascular implantable electronic devices in patients nearing end of life or requesting withdrawal of therapy
Padeletti, Luigi, Arnar, Davíð O. , Boncinelli, Lorenzo, Brachman, J., Camm, A. John , Daubert, Jean‐Claude, Kassam, Shireen , Deliëns, Luc , Glikson, M., Hayes, David L. , Israel, Carsten W. , Lampert, Rachel , Lobban, Trudie, Raatikainen, Pekka , Siegal, Gene P. , Vardas, Panagiotis, Reviewers:, Kirchhof, Paulus , Becker, Ruediger, Cosío, Francisco G., Loh, Peter , Cobbe, Stuart M., Grace, Andrew A. , Morgan, John , Lobban, Trudie, Reviewers:, Kirchhof, Paulus

Mayo Clinic

Europace | July 31, 2010 | Volume: 12 | Issue: 10 | Pages: 1480-1489

10.1093/europace/euq275 | PMID 20675674 Get It

Abstract The purpose of this Consensus Statement is to focus on implantable cardioverter-defibrillator (ICD) deactivation in patients with irreversible or terminal illness. This statement summarizes the opinions of the Task Force members, convened by the European Heart Rhythm Association (EHRA) and the Heart Rhythm Society (HRS), based on ethical and legal principles, as well as their own clinical, scientific, and technical experience. It is directed to all healthcare professionals who treat patients with implanted ICDs, nearing end of life, in order to improve the patient dying process. This statement is not intended to recommend or promote device deactivation. Rather, the ultimate judgement regarding this procedure must be made by the patient (or in special conditions by his/her legal representative) after careful communication about the deactivation's consequences, respecting his/her autonomy and clarifying that he/she has a legal and ethical right to refuse it. Obviously, the physician asked to deactivate the ICD and the industry representative asked to assist can conscientiously object to and refuse to perform device deactivation.
URINARY MATRIX CALCULI: OUR EXPERIENCE AT A SINGLE INSTITUTION
BaniHani, Ahmad, Segura, Joseph W., LeRoy, Andrew J.

Mayo Clinic

Journal of Urology | July 26, 2010 | Volume: 173 | Issue: 1 | Pages: 120-123

10.1097/01.ju.0000145868.18824.25 | PMID 15592051 Get It

Pneumocystis carinii Expresses an Active Rtt109 Histone Acetyltransferase
Han, Junhong , Zhang, Zhiguo , Kottom, Theodore J. , Zhang, Zhiguo , Limper, Andrew H. , Zhang, Zhiguo

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | July 23, 2010 | Volume: 44 | Issue: 6 | Pages: 768-776

10.1165/rcmb.2009-0443oc | PMID 20656950 Get It

Abstract Species in the genus Pneumocystis can cause severe pneumonia in immune-compromised hosts. The identification of specific targets present in Pneumocystis species, but lacking in mammalian hosts, is paramount to developing new means to treat this infection. One such potential protein is Rtt109, which is a type of histone acetyltransferase (HAT) required for DNA replication in fungi, but not found in mammals. Sequence orthologues of Rtt109 are present in other fungi, but are absent in mammals, making it a potential pan-specific target against medically relevant fungi. Accordingly, we sought to identify the presence of an Rtt109 in P. carinii. A Pneumocystis carinii (Pc) Rtt109 165-bp partial sequence was initially identified from the incomplete P. carinii genome database. Subsequently, a full-length, 1,128-bp cDNA with homology to Saccharomyces cerevisiae Rtt109 (39% Basic Local Alignment Search Tool (BLASTP)) was cloned and characterized. Sequence analysis of PcRtt109 indicated that the P. carinii molecule contains the putative catalytic aspartate present in yeast. We further demonstrated that the PcRtt109 expressed in rtt109Δ S. cerevisiae cells restored H3-K56 acetylation and the sensitivity toward DNA-damaging agents of rtt109Δ mutant cells. Purified PcRtt109 had the ability to acetylate lysine-56 of histone H3, similar to the ability of Schizosaccharomyces pombe Rtt109 protein. The site-directed mutagenesis of PcRtt109 D84A, a potential regulatory site in the Rtt109 HAT family, abolished H3 acetylation, whereas a DD218/219AA mutation that compromised the activity of ScRtt109 had little effect, demonstrating similarities and differences in Pneumocystis PcRtt109 compared with yeast Saccharomyces cerevisiae Rtt109. These results indicate that P. carinii contains an Rtt109 HAT molecule, and represent the complete identification and characterization of a HAT molecule from this important opportunistic fungal pathogen.
Progressive renal papillary calcification and ureteral stone formation in mice deficient for Tamm-Horsfall protein
Liu, Yan , Mo, Lan , Goldfarb, David S. , Evan, Andrew P., Liang, Feng‐Xia , Khan, Saeed R. , Wu, Xue‐Ru , Lieske, John C. , Goldfarb, David S

Mayo Clinic

American Journal of Physiology-Renal Physiology | July 12, 2010 | Volume: 299 | Issue: 3 | Pages: F469-F478

10.1152/ajprenal.00243.2010 | PMID 20591941 Get It

Mammalian urine contains a range of macromolecule proteins that play critical roles in renal stone formation, among which Tamm-Horsfall protein (THP) is by far the most abundant. While THP is a potent inhibitor of crystal aggregation in vitro and its ablation in vivo predisposes one of the two existing mouse models to spontaneous intrarenal calcium crystallization, key controversies remain regarding the role of THP in nephrolithiasis. By carrying out a long-range follow-up of more than 250 THP-null mice and their wild-type controls, we demonstrate here that renal calcification is a highly consistent phenotype of the THP-null mice that is age and partially gene dosage dependent, but is gender and genetic background independent. Renal calcification in THP-null mice is progressive, and by 15 mo over 85% of all the THP-null mice develop spontaneous intrarenal crystals. The crystals consist primarily of calcium phosphate in the form of hydroxyapatite, are located more frequently in the interstitial space of the renal papillae than intratubularly, particularly in older animals, and lack accompanying inflammatory cell infiltration. The interstitial deposits of hydroxyapatite observed in THP-null mice bear strong resemblances to the renal crystals found in human kidneys bearing idiopathic calcium oxalate stones. Compared with 24-h urine from the wild-type mice, that of THP-null mice is supersaturated with brushite (calcium phosphate), a stone precursor, and has reduced urinary excretion of citrate, a stone inhibitor. While less frequent than renal calcinosis, renal pelvic and ureteral stones and hydronephrosis occur in the aged THP-null mice. These results provide direct in vivo evidence indicating that normal THP plays an important role in defending the urinary system against calcification and suggest that reduced expression and/or decreased function of THP could contribute to nephrolithiasis.
O1‐07‐06: A genome‐wide association study of progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD)
Schellenberg, Gerard D., Sleiman, Patrick , Rademakers, Rosa , Kei, Lambertus, Silva, Rohan de , Wang, Li-San, Yu, Chang‐En , Hardy, John , Lees, Andrew, Müller, Ulrich , Höglinger, Günter U. , Wang, Li-San, Heutink, Peter , Swieten, John C. van , Farrer, Matthew J. , Devlin, Bernie , Håkonarson, Håkon , Dickson, Dennis W. , Hardy, John

Mayo Clinic

Alzheimer's & Dementia | July 11, 2010 | Volume: 6 | Issue: 4S_Part_3 | Pages: No page available

10.1016/j.jalz.2010.05.254 Get It

Operating Room Pooling and Parallel Surgery Processing Under Uncertainty
Batun, Sakine , Huschka, Todd R., Schaefer, Andrew J. , Denton, Brian T.

Mayo Clinic

INFORMS Journal on Computing | July 3, 2010 | Volume: 23 | Issue: 2 | Pages: 220-237

10.1287/ijoc.1100.0396 Get It

Operating room (OR) scheduling is an important operational problem for most hospitals. In this study, we present a novel two-stage stochastic mixed-integer programming model to minimize total expected operating cost given that scheduling decisions are made before the resolution of uncertainty in surgery durations. We use this model to quantify the benefit of pooling ORs as a shared resource and to illustrate the impact of parallel surgery processing on surgery schedules. Decisions in our model include the number of ORs to open each day, the allocation of surgeries to ORs, the sequence of surgeries within each OR, and the start time for each surgeon. Realistic-sized instances of our model are difficult or impossible to solve with standard stochastic programming techniques. Therefore, we exploit several structural properties of the model to achieve computational advantages. Furthermore, we describe a novel set of widely applicable valid inequalities that make it possible to solve practical instances. Based on our results for different resource usage schemes, we conclude that the impact of parallel surgery processing and the benefit of OR pooling are significant. The latter may lead to total cost reductions between 21% and 59% on average.